SIMPONI (golimumab) is the first and only subcutaneous anti-TNF therapy with convenient once-monthly dosing from day 1 for Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Non-Radiographic Axial Spondyloarthritis (Nr-axSpA) and a 4-weekly dosing schedule for Ulcerative Colitis (UC).1
Find out how SIMPONI can help your patients with moderate-to-severe Ulcerative Colitis.
Find out how SIMPONI can help your patients with AS, PsA, nr-axSpA, and RA.
SIMPONI is indicated for the treatment of:1
Active and progressive PsA in adult patients when response to disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate, when used alone or in combination with methotrexate (MTX).1
Severe, active AS in adults who have responded inadequately to conventional therapy.1
Moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.1
Moderately to severely active RA in combination with methotrexate, when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate.1
SIMPONI is also indicated for the treatment of severe, active and progressive RA in adults not previously treated with MTX.
Adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).1
Our patient support website will help your patients:
SIMPONI 50 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet for Pre-filled Syringe | Patient Information Leaflet for Pre-filled Pen
SIMPONI 100 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet for Pre-filled Pen
GB-GOL-00271 | Date of Preparation: September 2020